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Abstract 
Background: Endomyocardial fibrosis (EMF), the commonest restrictive cardiomyopathy worldwide, is characterized 
by inflammation and fibrosis of the endocardium. Inflammation in other parts of the body such as the peritoneum 
has been described and may explain the accumulation of ascites, a painful and disabling feature of this disease. 
We determined the efficacy and safety of prednisolone to prevent re-accumulation of ascites among EMF patients 
attending Mulago hospital cardiology service.
Methods: This was a pilot randomised placebo controlled trial with a 1:1 parallel design. Over a period of 10 months, 
participants were recruited and randomized to receive 1 mg/kg per day of prednisolone or placebo and were fol-
lowed for a maximum of 8 weeks. The primary outcome was re-accumulation of ascites from baseline (grade 2) to 
grade 3. Safety was assessed by self-reported side effects, physical exam, and laboratory assessment.
Results: Sixteen study participants were randomised to prednisolone, while nineteen were randomised to placebo. 
Six were lost to follow up (1-prednisolone arm, 5-placebo). Baseline characteristics were similar between groups. 
Prednisolone was safely administered in this setting. There was no statistically significant difference in the overall risk 
of developing grade 3 ascites over 8 weeks. RR (95 % confidence interval) 0.70 (0.43–1.11), P value 0.12. The rate of the 
primary outcome per 1000 person days of follow-up was also similar in both arms P value 0.63.
Conclusion: Short term prednisolone use was generally safe and did not prevent reaccumulation of ascites in this 
study population.
Trial registration number: ISRCTN63999319, 28/03/2013
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Background
Endomyocardial fibrosis (EMF) is the commonest 
restrictive cardiomyopathy worldwide . It was first recog-
nized during the 1940s and is still a cause of heart failure 
in Uganda [1]. A recent community-based study of over 
1000 people in Mozambique found an overall prevalence 
of 19.8 %. The commonest observed presentation of this 
disease is ascites which often requires repeated paracen-
tesis because current medical treatment which includes 
diuretics, digoxin and angiotensin converting enzyme 
inhibitors does not spare the patient from repeated para-
centeses [2].
While data on the management of ascites due to EMF 
are lacking, there is a state of clinical equipoise amongst 
physicians managing these patients on the usefulness 
of corticosteroid therapy in preventing accumulation of 
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ascites. The use of corticosteroids in the management of 
EMF, although not backed by randomised clinical trials, 
is informed by the pathological finding of global inflam-
mation and fibrosis which is not limited to the heart. The 
infiltration of the peritoneal cavity with leukocytes and 
exudative ascites suggests on-going inflammation of the 
peritoneum that is independent of disease duration [2]. It 
is therefore plausible that anti-inflammatory therapy can 
be useful to slow the progression of disease [2–6]. Indeed, 
anecdotal reports in African settings have described 
complete disappearance of ascites with corticosteroids 
therapy; however, safety, efficacy, and optimal duration 
of therapy of steroid use are all unknown. Prednisolone 
is an intermediate acting corticosteroid drug with pre-
dominant glucocorticoid and low mineral corticoid activ-
ity, making it useful for the treatment of a wide range 
of inflammatory and auto-immune conditions. It is well 
absorbed from the gastrointestinal tract, and widely dis-
tributed throughout the body plasma protein bound on 
transcortin and albumin. It was chosen because it is inex-
pensive and readily available in Uganda. It has a moderate 
side effect profile and the pill burden is limited compared 
to other corticosteroids such as dexamethasone.
In this patient population, abdominal swelling due to 
ascites is the commonest presenting feature of EMF, and 
is often accompanied by abdominal pain, general weak-
ness, and effort intolerance. The ascites is usually out 
of proportion to the amount of peripheral oedema [2]. 
Recurrent hospitalisation and paracenteses result in high 
social and economic costs to patients and caretakers. In 
this pilot study, we determined the safety and efficacy 
of prednisolone to prevent re-accumulation of ascites 
among EMF patients in Uganda.
Methods
This was a double-blind, randomised, placebo-controlled 
trial of patients with endomyocardial fibrosis and ascites 
conducted at Mulago National Referral Hospital (Kam-
pala, Uganda) from April 2012 to January 2013. Scientific 
and ethical approval was obtained from Makerere Uni-
versity College of Health Sciences School of Medicine 
Research and Ethics Committee (REC REF 2011-252), 
The National Drug Authority, and the trial registration 
number ISRCTN63999319 was obtained from www.con-
trolled-trials.com. We hypothesised that a sample of 19 
participants per group would give the study 80 % power 
to detect a 35  % difference between the two groups. 
This was based on the assumption that 95 % of patients 
would develop grade 3 ascites with standard care [2, 4]. 
Ascites was graded as follows using the International 
Ascites Club (IAC) grading grade 1: mild, only visible on 
ultrasound, grade 2: moderate symmetrical distension of 
abdomen and grade 3: large or gross ascites with marked 
abdominal distension [7]. Starting with all study partici-
pants at IAC grade 2, the primary end point for the effi-
cacy outcome was re-accumulation to IAC grade 3.
Participants were recruited from the outpatient cardiol-
ogy clinic and inpatient ward Mulago Hospital Complex 
with the assistance of two research assistants and a screen-
ing questionnaire. Inclusion criteria were (a) 13 years and 
older and (b) a diagnosis of EMF with ascites based on 
published echocardiographic criteria [8]. Participants were 
excluded if they were critically ill, had unstable vital param-
eters, or were pregnant. Those previously exposed to cor-
ticosteroids were allowed to enrol after a wash out period 
of 1 month. Written informed consent was obtained from 
all participants over 18  years of age. Assent and paren-
tal consent were obtained from participants younger than 
18  years. A data safety monitoring board (DSMB) was 
responsible for the review the unblinded data.
Study procedures
Baseline demographics and medical history were 
obtained using a standard questionnaire. A physical exam 
was performed to measure abdominal girth, weight, 
and grade of ascites. All participants with international 
ascites grade 3 ascites underwent paracentesis so that no 
participant had greater than international ascites grade 
2 ascites at baseline. Leukocyte count and albumin were 
measured in all samples of ascites. Venous blood was col-
lected for a complete blood count with differential, blood 
glucose, and albumin. The serum-to-ascites albumin gra-
dient (SAAG) was calculated as the difference between 
the ascites and serum albumin concentrations.
Participants were randomized to the prednisolone or 
placebo groups using a computer-generated sequence 
of random numbers generated by an epidemiologist. 
Blinding was done by using tablets of prednisolone and 
placebo with similar shape, size and taste from the manu-
facturer. The drugs were packaged by the manufacturer 
who did not know the study hypothesis into opaque tins. 
A sealed envelope containing the actual drug codes was 
kept by the study epidemiologist. The principal investiga-
tor assigned participants to a specific study arm while the 
research assistants dispensed the drugs to the patients 
who did not know to which study arm they had been 
assigned. The seal on the drug codes was only broken at 
the end after the final analysis had been done.
Prednisolone was administered orally at a dose of 1 mg/
kg per day or matching placebo at the same dose  with 
a ceiling dose of 60 mg per day. All study participants 
were followed up every 4  weeks until they reached the 
primary endpoint or for a maximum of 8  weeks. When 
the primary end point was reached, the study drugs were 
tapered off by halving the dose every week over a period 
of 1 month and then stopped. They were then redirected 
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to the cardiac clinic for regular follow up and care. At 
each follow-up visit, side-effects were assessed by self-
report using a standardized questionnaire and a physi-
cal exam. A random blood sugar was done at each visit 
using a contour glucometer. Adherence to treatment was 
assessed by pill count.
Statistical analysis
All analyses were performed using STATA software pack-
age, version 11 and it was on intention to treat basis. Base-
line characteristics of study participants were described 
as mean (standard deviation) for continuous variables or 
number (percent) for categorical variables, and were com-
pared using t-tests, Wilcoxon Rank Sum tests, Chi-square 
tests, or Fisher’s Exact tests as distributionally appropriate.
The primary outcome of this study was accumulation 
of grade 3 ascites requiring paracentesis. The relative risk 
of the primary outcome in the prednisolone group was 
calculated as the ratio of the proportion of participants 
who reached grade 3 ascites in the prednisolone group 
and the placebo group. In a separate analysis, the time to 
reaccumulation of grade 3 ascites was compared between 
groups. The frequencies of specific adverse events were 
described by study group and were compared using Chi-
square tests or Fisher’s Exact tests as distributionally 
appropriate. All tests were two-sided and a P value of 
<0.05 was considered statistically significant.
Results
Study flow chart is described in Fig. 1. All study partici-
pants received the study drug according to their allocated 
study arm. Overall adherence to treatment was 81 % and 
did not differ between groups P value 0.77. Baseline clini-
cal characteristics of study participants were similar in 
both groups (Table  1). Significant baseline laboratory 
characteristics include the following: peripheral eosino-
philia (>10  % of total leukocytes) was observed in only 
10 % of patients (Fig. 2), majority (97 %) had a transuda-
tive ascites, with 80  % having a lymphocytic predomi-
nance of cells on ascitic fluid analysis.
Excluded: 10 
Not meeng eligibility criteria.  
1 was under age, 
2 did not have ascites,  
1 had peritonis with a leaking 
umbilical hernia, 2 were taking 
prednisolone,  
4 had other diagnoses.   Randomised 35
Allocated to Placebo (19) Allocated to Prednisolone (16) 
Loss to follow up (1) Loss to follow up (5) 
Analyzed (15) Analyzed (14) 
45 Paents assessed for 
eligibility 
Fig. 1 Participant flow chart. Showing the number of patients screened, recruited, randomized, allocated to the prednisolone or placebo groups, 
and analyzed
Page 4 of 6Nabunnya et al. BMC Res Notes  (2015) 8:783 
Primary outcome
The mean follow-up was 34  days in the prednisolone 
arm and 35 days in the placebo arm. Of the 29 patients 
who completed longitudinal follow-up, 21 reached the 
primary endpoint [n  =  9 (60  %) vs n  =  12 (86  %) for 
prednisolone vs placebo, respectively; relative risk (95 % 
confidence interval, CI) 0.7 (0.439–1.114), P = 0.12]. The 
rate of the primary outcome per 1000 person days of fol-
low up in the prednisolone group was 17.6 (95 % CI 9.1–
33.8) vs 25.6 (14.6–45.1) in the placebo group (P = 0.63) 
(Fig. 3).
Adverse events
All adverse events were reviewed by the DSMB. There 
were three serious (>grade 3) adverse events over the 
course of the study. One patient in the prednisone group 
was hospitalized for malaria, and was discharged after 
3  days. In the placebo group, one was hospitalized for 
spontaneous bacterial peritonitis, and was discharged 
after 5  days. One participant in the placebo group died 
before the first follow-up visit from an acute illness 
characterized by severe dyspnea as described by family 
members.
The most common minor (grade 2 or less) adverse event 
was epigastric pain (73  %), followed by muscle pain and 
melena (Table  2). No study participant had a significant 
Table 1 Baseline demographic characteristics of  study 
participants





Mean age 27.947 (SD 9.50) 27.125 (SD 8.82) 0.709
Sex 1.000
 Male 5 (36.84) 7 (31.25)
 Female 11 (68.75) 12 (63.16)
Level of education 0.491
 No formal education 2 (12.50) 4 (21.05)
 Primary 12 (75.00) 10 (52.63)
 Secondary 2 (12.50) 5 (26.32)
Occupation 0.636
 Unemployed 11 (68.75) 13 (68.42)
 Employed 5 (31.25) 6 (31.58)
Duration of disease 0.529
 <1 year 13 (81.25) 11 (57.89)
 1–2 years 1 (6.25) 1 (5.26)
 3–5 years 1 (6.25) 3 (15.79)
 >5 years 1 (6.25) 4 (21.05)
Family history of EMF 0.398
 Yes 4 (25.00) 3 (15.795)
 No 12 (75.00) 16 (84.21)
Paracentesis in prior 
3 months
0.763
 None 6 (37.50) 8 (42.11)
 Once 1 (6.25) 3 (15.79)
 Twice 4 (25.00) 4 (21.05)
 Thrice 3 (18.75) 1 (5.26)
 More than 3 times 2 (12.50) 3 (15.79)
Mean weight 47.894 (SD 10.32) 45.625 (SD 15.56) 0.703
Blood pressure 0.234
 <90/60 0 (0.00) 3 (15.79)
 90/60–139/89 16 (100.00) 16 (84.21)
Temperature 0.457
 <35 1 (6.25) 0 (0.00)
 35–37.5 15 (93.75) 19 (100.00)
Random blood sugar 0.481
 <4 mmol/dl 4 (25) 6 (31.58)
 4–11 mmol/dl 12 (75.00) 13 (68.42)
White cell count 
(WBC)
0.758
 >10,000 1 (8.33) 1 (5.88)
 4000–10,000 7 (58.33) 8 (47.06)
 <4000 4 (33.33) 8 (47.06)
Eosinophilia (>10 % 
WBC)
2 (16.67) 1 (5.88) 0.348
Haemoglobin 0.793
 >14 mg/dl 9 (75.00) 12 (70.59)
 12–14 mg/dl 3 (25.00) 5 (29.41)
SAAG 0.414
 <1.1 1 (8.33) 0 (0.00)
 >1.1 11 (91.67) 17 (100)
Table 1 continued








 >40 % 15 (93.75) 13 (68.42)
 <40 % 1 (6.25) 6 (31.58)




















Fig. 2 Histogram of percentage eosinophil distribution among 
participants on prednisolone and placebo arms, showing only 10 % 
of participants having eosinophilia
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drop in haemoglobin or required a blood transfusion 
from gastrointestinal bleeding. There was one patient in 
the prednisolone group who developed diabetes with a 
random blood sugar of 24.5 mmol/dl. For this patient, the 
prednisolone was tapered off and the random blood sugar 
fell to 17.5 mmol/dl and she was referred for further care.
Discussion
In this clinical trial of short-term prednisolone use in 
symptomatic EMF with ascites, we found that predniso-
lone does not appear to reduce the re-accumulation of 
ascites.
That prednisolone did not reduce reaccumulation of 
ascites can be explained by the fact that we found little 
evidence of ongoing peritoneal inflammation (less eosin-
ophilia and predominantly transudative ascites) contrary 
to earlier studies [12].
To our knowledge, this is the first clinical trial of anti-
inflammatory treatment for EMF. The baseline character-
istics of our subjects were mostly in agreement with what 
is known about the risk factors for this disease [9]. The 
differences, of a small number of our study population 
having eosinophilia and majority having transudative 
ascites could have been because we saw these patients 
late after the acute stage of disease had passed [10], or 
it could be that the picture of EMF in our context is dif-
ferent than the patients described by Rutakingirwa et al. 
[11].
In this study population, there was no significant differ-
ence in the occurrence of adverse effects among the two 
study arms. There was a number of self-limited gastroin-
testinal bleeds but none requiring blood transfusion [13]. 
Prednisolone increased the risk of developing epigas-
tric pain and muscle pains by 23 and 12  % respectively, 
but this was not statistically significant between groups. 
Only one study participant developed high random 
blood sugar which reduced on stopping the study drug. 
The short duration of drug exposure was the main study 
limitation.
Conclusion
Prednisolone did not prevent reaccumulation of ascites 
in this patient population but was safe. Exploratory stud-
ies in the aetiology and pathophysiology of this disease 
may throw more light and guide therapeutic attempts 
among such patients.
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Fig. 3 Kaplan Meier curve comparing the proportion of patients 
prevented from re-accumulating ascites in the prednisolone and 
placebo arms. There was no statistically significant difference in the 
rate of re-accumulation between the groups (P = 0.63)
Table 2 Adverse events of study participants
Adverse event Prednisolone, n (%) Placebo, n (%) P value
Epigastric pain 11 (73.33) 7 (50.00) 0.201
Malena 1 (6.67) 3 (21.43) 0.328
Muscle pain 4 (26.67) 2 (14.29) 0.417
Blood pressure 0.273
 <90/60 1 (6.67) 3 (21.43)
 90/60–139/89 14 (93.33) 11 (78.57)
Random blood sugar
 <4 mmol/dl 4 (26.67) 5 (35.71) 0.685
 7–11 mmol/dl 3 (60) 2 (40) 0.361
 >11 mmol/dl 1 (6.67) 0 (0.00) 0.723
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